Psoriasis and Smoking

Richer, Vincent; Roubille, Camille; Fleming, Patrick; Starnino, Tara; McCourt, Collette; McFarlane, Alexandra; Siu, Stephanie; Kraft, John; Lynde, Charles; Pope, Janet; Keeling, Stephanie; Dutz, Jan P.; Bessette, Louis; Gulliver, Wayne; Haraoui, Boulos; Bissonnette, Robert

doi:10.1177/1203475415616073

Cited by 55 publications

(17 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A previously published meta-analysis determined that that smoking is an independent risk factor for the development of psoriasis and that patients with established psoriasis continue to smoke more than patients without psoriasis [9]. Another meta-analysis showed not only a positive association between the presence of psoriasis and the prevalence of smoking, but also between tobacco and the severity of psoriasis [10].…”

Section: Smokingmentioning

confidence: 99%

Psoriasis and Cardiovascular Risk: A Comprehensive Review

Masson

Lobo²,

Molinero³

2020

Adv Ther

117

129

View full text Add to dashboard Cite

Psoriasis is a systemic inflammatory disorder that involves complex pathogenic interactions between the innate and adaptive immune systems. Individuals with psoriasis have an increased risk of developing other chronic health diseases such cardiovascular disorders. The high incidence of cardiovascular events in the population with psoriasis could be explained by several mechanisms. The high prevalence of traditional cardiovascular risk factors and metabolic abnormalities contributes to the high cardiovascular burden in patients with psoriasis. Likewise, the presence of systemic inflammation in combination with metabolic abnormalities may act in a synergistic manner to increase cardiovascular risk in these patients. This review focused on epidemiologic and clinical evidence linking psoriasis to cardiovascular risk factors and cardiovascular disease. We described the possible pathophysiological mechanisms that justify this association and analyzed the best way to stratify the cardiovascular risk in patients with psoriasis. We also described the usefulness of the therapies frequently used in cardiovascular prevention and analyzed the impact of the specific psoriasis medication on cardiovascular risk factors or major atherosclerotic events. Knowledge of the application of different cardiovascular prevention strategies could mean an advantage in performing the difficult task of estimating cardiovascular risk and treating cardiovascular risk factors in this particular group of patients.

show abstract

Section: Smokingmentioning

confidence: 99%

Psoriasis and Cardiovascular Risk: A Comprehensive Review

Masson

Lobo²,

Molinero³

2020

Adv Ther

117

129

View full text Add to dashboard Cite

show abstract

“…Various studies have shown increased prevalence of cigarette smoking and alcohol consumption in patients with psoriasis [ 128 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 ]. A recent meta-analysis also demonstrated a significant association between smoking and psoriasis disease severity [ 158 ]. However, it is not clearly defined whether cigarette smoking and alcohol consumption may increase the risk of developing psoriasis, or whether they occur as a consequence of psoriasis-associated psychological stress.…”

Section: Psoriasis and Cardiovascular Risk Factorsmentioning

confidence: 99%

Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment

Lan

2017

IJMS

147

121

View full text Add to dashboard Cite

Psoriasis is a common and chronic inflammatory disease of the skin. It may impair the physical and psychosocial function of patients and lead to decreased quality of life. Traditionally, psoriasis has been regarded as a disease affecting only the skin and joints. More recently, studies have shown that psoriasis is a systemic inflammatory disorder which can be associated with various comorbidities. In particular, psoriasis is associated with an increased risk of developing severe vascular events such as myocardial infarction and stroke. In addition, the prevalence rates of cardiovascular risk factors are increased, including hypertension, diabetes mellitus, dyslipidemia, obesity, and metabolic syndrome. Consequently, mortality rates have been found to be increased and life expectancy decreased in patients with psoriasis, as compared to the general population. Various studies have also shown that systemic treatments for psoriasis, including methotrexate and tumor necrosis factor-α inhibitors, may significantly decrease cardiovascular risk. Mechanistically, the presence of common inflammatory pathways, secretion of adipokines, insulin resistance, angiogenesis, oxidative stress, microparticles, and hypercoagulability may explain the association between psoriasis and cardiometabolic disorders. In this article, we review the evidence regarding the association between psoriasis and cardiovascular comorbidities, focusing on severe vascular events, cardiovascular risk factors and implications for treatment.

show abstract

“…Studies have revealed a significant increase in Hcy levels in smokers compared with non-smokers [27–30]. Meanwhile, a systematic literature review and meta-analysis identified significant association between the prevalence of smoking and psoriasis [31].…”

Section: Possible Causes Of High Hcy Levels In Psoriasismentioning

confidence: 99%

Homocysteine and psoriasis

Lin

Meng²,

Song

2019

Bioscience Reports

View full text Add to dashboard Cite

Psoriasis is caused by a complex interplay among the immune system, genetic background, autoantigens, and environmental factors. Recent studies have demonstrated that patients with psoriasis have a significantly higher serum homocysteine (Hcy) level and a higher prevalence of hyperhomocysteinaemia (HHcy). Insufficiency of folic acid and vitamin B12 can be a cause of HHcy in psoriasis. Hcy may promote the immuno-inflammatory process in the pathogenesis of psoriasis by activating Th1 and Th17 cells and neutrophils, while suppressing regulatory T cells. Moreover, Hcy can drive the immuno-inflammatory process by enhancing the production of the pro-inflammatory cytokines in related to psoriasis. Hcy can induce nuclear factor kappa B activation, which is critical in the immunopathogenesis of psoriasis. There may be a link between the oxidative stress state in psoriasis and the effect of HHcy. Hydrogen sulfide (H2S) may play a protective role in the pathogenesis of psoriasis and the deficiency of H2S in psoriasis may be caused by HHcy. As the role of Hcy in the pathogenesis of psoriasis is most likely established, Hcy can be a potential therapeutic target for the treatment of psoriasis. Systemic folinate calcium, a folic acid derivative, and topical vitamin B12 have found to be effective in treating psoriasis.

show abstract

Psoriasis and Smoking

Abstract: This literature review is in favor of a positive association between the prevalence of smoking and psoriasis as well as an association between smoking and severity of psoriasis.

Cited by 55 publications

References 42 publications

Psoriasis and Cardiovascular Risk: A Comprehensive Review

Psoriasis and Cardiovascular Risk: A Comprehensive Review

Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment

Homocysteine and psoriasis

Contact Info

Product

Resources

About